News
13h
Stocktwits on MSNNovo Nordisk To Reportedly Cut Yearly Bonus For Denmark Employees: Retail Expects Stock To Hit $80 By Year-End
Drugmaker Novo Nordisk (NVO) will offer a reduced 2025 yearly bonus to its employees in Denmark due to the company’s lowered ...
As Novo Nordisk transitions from the leadership of longtime CEO Lars Fruergaard Jørgensen to newly appointed chief Maziar ...
2d
Stocktwits on MSNNovo Nordisk Freezes Hiring To Cut Costs, Says Report: Retail Sees Stock Surpassing $100-Mark In A Year
Danish drugmaker Novo Nordisk (NVO) has implemented a hiring freeze, which will apply across all markets and departments, ...
7d
Zacks.com on MSNWill New CEO's Leadership Propel Novo Nordisk's Next Growth Wave?
Maziar Mike Doustdar takes office as NVO's new CEO, bringing a proven global growth record to tackle rising obesity market ...
No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...
Novo Nordisk, the Denmark-based pharmaceutical company that makes Ozempic and Wegovy, looks like it's being toppled off its ...
Lars Fruergaard Jørgensen says: “Serving as Novo Nordisk’s CEO for the past eight years has been a privilege and an experience that I will always cherish.
After an unusual first quarter in which seven of the biopharma industry’s | Several U.S. pharma companies that had posted ...
Lars Rebien Sørensen has pharmaceutical industry expertise from his 16-year tenure as CEO. In the pre-market trading, 5.37% lesser at $62.60 on the New York Stock Exchange.
CEO Lars Fruergaard Jørgensen said that efforts to bolster supply of the wildly popular weight-loss drug had resulted in the drug's removal from a drug shortage list. "Given the significant ...
Lars Fruergaard Jørgensen Good. Thank you, Truong. First, Karsten, on NovoSeven growth. Karsten Munk Knudsen Yes. So we've been looking at our -- at NovoSeven for quite a number of years now.
CEO Lars Fruergaard Jørgensen told shareholders at its Annual General Meeting that it was pursuing legal action against companies it believes to be violating its intellectual property.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results